

Newbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	7.9	76.2	(27.8-165.9)	Male	16	5.3	301.0	(171.9-488.8)
Female	3	2.6	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
Female	3	1.2	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	4.6	107.6	(34.7-251.2)
Female	44	32.1	137.2	(99.7-184.2)	Female	4	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.6	nc	(nc-nc)
Male	11	9.0	122.5	(61.0-219.1)	<u>Ovary</u>				
Female	10	8.0	124.4	(59.6-228.8)	Female	4	2.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	2.3	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	40	32.5	123.0	(87.8-167.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	4	4.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
Female	2	2.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	7	5.8	121.1	(48.5-249.5)
Male	0	3.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.1	nc	(nc-nc)	Female	8	7.5	106.2	(45.7-209.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.0	nc	(nc-nc)	Male	113	112.3	100.7	(83.0-121.0)
Female	1	0.8	nc	(nc-nc)	Female	113	103.7	108.9	(89.8-131.0)
<u>Lung and Bronchus</u>									
Male	9	14.9	60.5	(27.6-114.9)					
Female	11	14.2	77.3	(38.5-138.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newburyport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	20.7	106.3	(66.6-160.9)	Male	24	13.5	178.2	(114.2-265.2)
Female	8	8.5	93.9	(40.4-185.0)	Female	16	11.6	137.7	(78.6-223.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.8	nc	(nc-nc)	Male	1	4.0	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	Female	6	3.6	165.0	(60.2-359.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.7	nc	(nc-nc)	Male	14	11.8	118.7	(64.9-199.2)
Female	91	91.5	99.4	(80.1-122.1)	Female	8	11.3	71.0	(30.6-139.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	3.0	nc	(nc-nc)	Male	17	9.8	173.7	(101.1-278.1)
<u>Colon / Rectum</u>					Female	3	4.7	nc	(nc-nc)
Male	25	23.0	108.9	(70.5-160.8)	<u>Ovary</u>				
Female	26	26.0	99.9	(65.3-146.5)	Female	9	8.4	107.6	(49.1-204.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.7	105.1	(38.4-228.8)	Male	7	7.1	98.0	(39.3-202.0)
Female	2	1.6	nc	(nc-nc)	Female	8	8.4	95.7	(41.2-188.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	85	77.7	109.5	(87.4-135.4)
Female	2	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.9	123.2	(45.0-268.1)
Male	11	11.5	96.0	(47.9-171.8)	Female	6	3.3	183.6	(67.1-399.7)
Female	4	7.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.2	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	9	5.1	176.6	(80.6-335.2)
<u>Leukemia</u>					Female	18	15.8	113.9	(67.5-180.1)
Male	8	8.1	99.3	(42.8-195.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	6.6	75.6	(24.4-176.5)	Female	16	21.2	75.3	(43.0-122.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	7.2	nc	(nc-nc)	Male	293	280.0	104.6	(93.0-117.3)
Female	3	2.6	nc	(nc-nc)	Female	306	309.8	98.8	(88.0-110.5)
<u>Lung and Bronchus</u>									
Male	30	38.1	78.8	(53.2-112.5)					
Female	43	43.6	98.7	(71.4-132.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Newton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	93	98.2	94.7	(76.4-116.0)	Male	69	61.3	112.5	(87.5-142.4)
Female	42	36.8	114.1	(82.2-154.3)	Female	67	50.3	133.3	(103.3-169.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	21	17.4	120.9	(74.8-184.9)	Male	25	18.2	137.4	(88.9-202.8)
Female	17	15.7	108.1	(62.9-173.1)	Female	18	15.5	116.1	(68.7-183.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	3.0	nc	(nc-nc)	Male	56	54.5	102.7	(77.6-133.4)
Female	457	381.0	119.9	(109.2-131.5)	Female	53	48.3	109.7	(82.1-143.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	12.9	92.8	(47.9-162.1)	Male	40	42.6	93.9	(67.1-127.9)
<u>Colon / Rectum</u>					Female	26	20.0	130.0	(84.9-190.5)
Male	90	105.8	85.0	(68.4-104.5)	<u>Ovary</u>				
Female	91	112.1	81.1	(65.3-99.6)	Female	39	35.3	110.4	(78.5-151.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	25.5	35.2	(16.1-66.9)	Male	34	33.0	103.2	(71.4-144.2)
Female	7	7.0	99.8	(40.0-205.7)	Female	48	36.2	132.5	(97.7-175.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	7.1	nc	(nc-nc)	Male	362	337.6	107.2	(96.5-118.9)
Female	4	6.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	18	22.5	79.9	(47.3-126.2)
Male	51	50.3	101.5	(75.6-133.4)	Female	15	14.2	105.4	(59.0-173.9)
Female	22	30.7	71.7	(44.9-108.6)	<u>Testis</u>				
<u>Larynx</u>					Male	13	11.1	117.2	(62.3-200.4)
Male	9	14.0	64.3	(29.4-122.1)	<u>Thyroid</u>				
Female	1	4.7	nc	(nc-nc)	Male	34	22.2	153.1	(106.0-214.0)
<u>Leukemia</u>					Female	82	68.8	119.3	(94.8-148.0)
Male	46	38.3	120.2	(88.0-160.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	29.2	85.7	(55.5-126.6)	Female	87	87.4	99.6	(79.8-122.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	28	31.9	87.9	(58.4-127.0)	Male	1203	1268.4	94.8	(89.6-100.4)
Female	11	10.9	100.8	(50.3-180.5)	Female	1400	1316.6	106.3	(100.8-112.1)
<u>Lung and Bronchus</u>									
Male	127	174.6	72.8	(60.6-86.6)					
Female	148	185.0	80.0	(67.6-94.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norfolk

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	10.6	75.6	(32.6-149.0)	Male	12	8.3	145.2	(75.0-253.7)
Female	3	2.6	nc	(nc-nc)	Female	6	4.4	135.5	(49.5-294.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.6	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	7	7.2	96.9	(38.8-199.7)
Female	53	35.7	148.3	(111.1-194.0)	Female	0	3.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.7	nc	(nc-nc)
Male	12	13.5	88.6	(45.7-154.8)	<u>Ovary</u>				
Female	7	8.2	85.4	(34.2-176.0)	Female	1	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.4	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	49	47.6	103.0	(76.2-136.2)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	2.8	217.0	(79.2-472.4)
Male	6	7.5	79.6	(29.1-173.3)	Female	2	1.0	nc	(nc-nc)
Female	2	2.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.2	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	4.0	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.2	83.8	(30.6-182.5)
Male	3	4.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.3	nc	(nc-nc)	Female	7	8.2	85.7	(34.3-176.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	4.6	151.5	(60.7-312.2)	Male	157	167.3	93.8	(79.7-109.7)
Female	0	0.9	nc	(nc-nc)	Female	113	111.6	101.3	(83.5-121.8)
<u>Lung and Bronchus</u>									
Male	20	20.4	98.1	(59.9-151.5)					
Female	10	14.2	70.3	(33.6-129.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	15.6	121.9	(73.3-190.3)	Male	6	9.8	61.5	(22.5-133.9)
Female	13	6.4	203.1	(108.0-347.3)	Female	5	8.2	60.9	(19.6-142.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.7	182.1	(58.7-424.9)	Male	5	2.9	173.4	(55.9-404.7)
Female	1	2.6	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	8	8.7	92.4	(39.8-182.0)
Female	52	60.8	85.5	(63.8-112.1)	Female	6	8.1	73.7	(26.9-160.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.0	nc	(nc-nc)	Male	8	6.7	120.2	(51.7-236.8)
<u>Colon / Rectum</u>					Female	2	3.3	nc	(nc-nc)
Male	26	16.7	155.4	(101.5-227.7)	<u>Ovary</u>				
Female	24	19.3	124.4	(79.7-185.1)	Female	6	5.7	104.7	(38.2-227.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	4.0	249.0	(119.2-458.0)	Male	2	5.2	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	11	6.3	174.9	(87.2-313.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	52	52.7	98.6	(73.6-129.3)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.6	140.3	(45.2-327.4)
Male	14	7.9	176.8	(96.6-296.7)	Female	3	2.5	nc	(nc-nc)
Female	2	5.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.0	nc	(nc-nc)
Male	2	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	4	0.8	nc	(nc-nc)	Male	3	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	11	10.7	103.1	(51.4-184.5)
Male	5	6.1	82.6	(26.6-192.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.0	141.4	(56.6-291.3)	Female	11	13.8	80.0	(39.9-143.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	5.0	219.1	(109.2-392.1)	Male	240	200.5	119.7	(105.0-135.8)
Female	3	1.8	nc	(nc-nc)	Female	220	217.6	101.1	(88.2-115.4)
<u>Lung and Bronchus</u>									
Male	41	27.8	147.4	(105.7-199.9)					
Female	42	31.9	131.8	(95.0-178.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	27.6	134.1	(94.4-184.8)	Male	23	18.2	126.4	(80.1-189.7)
Female	14	11.3	123.6	(67.5-207.3)	Female	15	15.8	94.9	(53.1-156.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.5	109.5	(40.0-238.4)	Male	4	5.3	nc	(nc-nc)
Female	5	5.0	100.9	(32.5-235.4)	Female	5	4.8	105.0	(33.8-245.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	4	0.9	nc	(nc-nc)	Male	13	16.2	80.2	(42.7-137.1)
Female	117	119.9	97.6	(80.7-117.0)	Female	17	15.0	113.7	(66.2-182.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.3	nc	(nc-nc)	Male	12	13.1	91.5	(47.2-159.8)
<u>Colon / Rectum</u>					Female	4	6.2	nc	(nc-nc)
Male	27	31.2	86.4	(56.9-125.8)	<u>Ovary</u>				
Female	40	35.4	112.9	(80.6-153.7)	Female	11	11.0	100.4	(50.1-179.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.4	94.2	(37.7-194.1)	Male	13	9.5	137.3	(73.1-234.9)
Female	1	2.1	nc	(nc-nc)	Female	13	11.2	115.9	(61.6-198.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.3	217.6	(70.1-507.8)	Male	115	98.9	116.3	(96.0-139.6)
Female	4	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.5	91.8	(33.5-199.7)
Male	19	15.3	124.0	(74.6-193.6)	Female	5	4.5	110.7	(35.7-258.3)
Female	5	9.5	52.7	(17.0-122.9)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.8	132.3	(42.6-308.8)
Male	1	4.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.4	nc	(nc-nc)	Male	9	7.2	124.9	(57.0-237.1)
<u>Leukemia</u>					Female	31	22.4	138.5	(94.1-196.5)
Male	12	11.3	105.9	(54.6-185.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	9.2	97.5	(44.5-185.1)	Female	17	26.5	64.2	(37.4-102.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	9.5	nc	(nc-nc)	Male	391	372.1	105.1	(94.9-116.0)
Female	4	3.3	nc	(nc-nc)	Female	412	410.2	100.4	(91.0-110.6)
<u>Lung and Bronchus</u>									
Male	35	49.5	70.7	(49.3-98.4)					
Female	59	55.6	106.2	(80.8-137.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Attleborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	24.3	74.2	(44.0-117.3)	Male	19	17.2	110.5	(66.5-172.6)
Female	6	8.9	67.6	(24.7-147.1)	Female	20	14.5	137.6	(84.0-212.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.4	129.8	(52.0-267.5)	Male	1	4.9	nc	(nc-nc)
Female	6	4.5	132.7	(48.4-288.8)	Female	5	3.9	128.9	(41.5-300.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	18	15.2	118.5	(70.2-187.3)
Female	106	110.2	96.2	(78.7-116.3)	Female	12	12.6	95.1	(49.1-166.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	4.3	nc	(nc-nc)	Male	12	12.9	93.2	(48.1-162.8)
<u>Colon / Rectum</u>					Female	7	5.4	130.3	(52.2-268.4)
Male	38	28.7	132.2	(93.6-181.5)	<u>Ovary</u>				
Female	27	28.1	96.2	(63.4-140.0)	Female	7	9.8	71.1	(28.5-146.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	7.0	100.6	(40.3-207.3)	Male	6	8.6	69.9	(25.5-152.2)
Female	1	1.7	nc	(nc-nc)	Female	10	8.6	116.0	(55.5-213.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.4	nc	(nc-nc)	Male	103	95.0	108.4	(88.5-131.5)
Female	1	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.0	nc	(nc-nc)
Male	10	15.0	66.8	(32.0-122.9)	Female	1	3.5	nc	(nc-nc)
Female	7	8.4	83.4	(33.4-171.8)	<u>Testis</u>				
<u>Larynx</u>					Male	4	4.3	nc	(nc-nc)
Male	9	3.9	230.9	(105.4-438.4)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	4	7.5	nc	(nc-nc)
<u>Leukemia</u>					Female	30	23.0	130.3	(87.9-186.0)
Male	8	10.4	76.7	(33.0-151.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.7	64.7	(20.8-150.9)	Female	25	24.6	101.7	(65.8-150.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	9.2	98.0	(44.7-186.1)	Male	356	349.1	102.0	(91.6-113.1)
Female	1	2.8	nc	(nc-nc)	Female	342	360.0	95.0	(85.2-105.6)
<u>Lung and Bronchus</u>									
Male	47	44.9	104.7	(76.9-139.2)					
Female	44	46.9	93.8	(68.2-126.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.1	nc	(nc-nc)	Male	5	3.4	148.6	(47.9-346.7)
Female	1	1.8	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	20	19.8	101.1	(61.7-156.2)	Female	1	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.0	nc	(nc-nc)
Male	6	5.7	104.6	(38.2-227.6)	<u>Ovary</u>				
Female	3	5.5	nc	(nc-nc)	Female	4	1.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.4	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	21	19.1	110.0	(68.0-168.1)
Female	2	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	3	2.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.8	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.4	nc	(nc-nc)	Female	6	4.5	134.2	(49.0-292.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.8	nc	(nc-nc)	Male	65	69.5	93.5	(72.1-119.1)
Female	0	0.5	nc	(nc-nc)	Female	53	66.8	79.4	(59.5-103.8)
<u>Lung and Bronchus</u>									
Male	7	9.2	75.8	(30.3-156.1)					
Female	6	9.2	64.9	(23.7-141.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

North Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	15.2	72.4	(36.1-129.6)	Male	17	10.3	164.8	(95.9-263.8)
Female	9	5.2	173.6	(79.2-329.6)	Female	14	8.0	175.2	(95.7-294.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	3.1	195.5	(71.4-425.4)	Male	3	3.0	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	11	9.1	121.3	(60.5-217.0)
Female	70	62.8	111.5	(86.9-140.8)	Female	8	7.2	110.6	(47.6-217.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.2	nc	(nc-nc)	Male	4	7.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	3.1	nc	(nc-nc)
Male	20	17.5	114.5	(69.9-176.9)	<u>Ovary</u>				
Female	16	16.1	99.2	(56.7-161.2)	Female	3	5.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.3	140.5	(51.3-305.9)	Male	2	5.3	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	4	5.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.3	nc	(nc-nc)	Male	55	58.1	94.7	(71.3-123.2)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.7	nc	(nc-nc)
Male	8	8.9	90.1	(38.8-177.5)	Female	0	2.0	nc	(nc-nc)
Female	2	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.0	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.7	nc	(nc-nc)	Male	2	4.2	nc	(nc-nc)
<u>Leukemia</u>					Female	16	12.1	132.1	(75.5-214.6)
Male	9	6.2	145.3	(66.3-275.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.3	139.3	(50.9-303.3)	Female	15	14.2	105.9	(59.3-174.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	5.6	nc	(nc-nc)	Male	204	211.9	96.3	(83.5-110.4)
Female	2	1.6	nc	(nc-nc)	Female	203	205.1	99.0	(85.8-113.6)
<u>Lung and Bronchus</u>									
Male	20	28.1	71.1	(43.4-109.9)					
Female	16	27.8	57.6	(32.9-93.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	30.0	100.1	(67.5-142.9)	Male	10	19.4	51.5	(24.6-94.7)
Female	9	11.6	77.6	(35.4-147.3)	Female	12	17.2	69.8	(36.0-121.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.5	109.2	(39.9-237.7)	Male	0	5.7	nc	(nc-nc)
Female	7	5.2	133.8	(53.6-275.6)	Female	6	4.9	121.4	(44.3-264.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	16	17.1	93.4	(53.4-151.7)
Female	142	125.5	113.2	(95.3-133.4)	Female	15	15.6	96.0	(53.7-158.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	4.5	nc	(nc-nc)	Male	10	14.0	71.4	(34.2-131.3)
<u>Colon / Rectum</u>					Female	9	6.5	137.6	(62.8-261.2)
Male	33	33.1	99.6	(68.5-139.8)	<u>Ovary</u>				
Female	33	35.7	92.3	(63.5-129.7)	Female	17	11.8	144.5	(84.1-231.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	8.2	110.4	(50.4-209.5)	Male	9	10.3	87.5	(39.9-166.2)
Female	3	2.2	nc	(nc-nc)	Female	15	11.4	131.5	(73.6-216.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.3	nc	(nc-nc)	Male	82	110.2	74.4	(59.2-92.4)
Female	2	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	7.0	nc	(nc-nc)
Male	12	16.2	73.9	(38.2-129.2)	Female	5	4.5	110.2	(35.5-257.2)
Female	12	9.9	120.9	(62.4-211.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	3.9	nc	(nc-nc)
Male	3	4.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.5	nc	(nc-nc)	Male	5	7.5	67.0	(21.6-156.4)
<u>Leukemia</u>					Female	11	24.8	44.4	(22.1-79.4)
Male	9	11.7	76.6	(35.0-145.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	9.4	85.4	(36.8-168.2)	Female	31	29.0	106.8	(72.5-151.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	10.4	105.7	(52.7-189.2)	Male	317	402.6	78.7	(70.3-87.9)
Female	1	3.5	nc	(nc-nc)	Female	425	430.5	98.7	(89.5-108.6)
<u>Lung and Bronchus</u>									
Male	40	54.1	73.9	(52.8-100.7)					
Female	53	58.5	90.5	(67.8-118.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	14.2	133.5	(80.3-208.4)	Male	6	9.7	62.2	(22.7-135.3)
Female	8	5.4	147.9	(63.7-291.4)	Female	7	7.9	89.1	(35.7-183.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	4	2.8	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	6	8.5	70.4	(25.7-153.2)
Female	59	61.9	95.4	(72.6-123.0)	Female	4	7.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.2	nc	(nc-nc)	Male	3	7.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	5	3.1	161.7	(52.1-377.4)
Male	10	16.4	61.0	(29.2-112.2)	<u>Ovary</u>				
Female	22	16.8	131.0	(82.0-198.3)	Female	4	5.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.0	125.2	(40.4-292.3)	Male	9	5.0	181.7	(82.9-345.0)
Female	0	1.0	nc	(nc-nc)	Female	5	5.3	95.0	(30.6-221.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.2	nc	(nc-nc)	Male	56	53.9	103.8	(78.4-134.8)
Female	2	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.4	nc	(nc-nc)
Male	4	8.3	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.9	nc	(nc-nc)
Male	3	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
<u>Leukemia</u>					Female	8	11.4	69.9	(30.1-137.8)
Male	11	5.8	188.5	(93.9-337.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.4	nc	(nc-nc)	Female	17	13.8	122.9	(71.5-196.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	5.2	nc	(nc-nc)	Male	175	198.1	88.4	(75.8-102.5)
Female	0	1.6	nc	(nc-nc)	Female	186	205.3	90.6	(78.1-104.6)
<u>Lung and Bronchus</u>									
Male	17	26.2	64.8	(37.7-103.7)					
Female	18	28.2	63.9	(37.9-101.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northbridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	19	15.3	123.9	(74.6-193.5)	Male	5	10.1	49.5	(16.0-115.5)
Female	8	6.2	129.8	(55.9-255.8)	Female	6	8.7	69.3	(25.3-150.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	3.0	nc	(nc-nc)	Male	6	2.9	205.2	(74.9-446.7)
Female	1	2.7	nc	(nc-nc)	Female	4	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	6	9.0	66.6	(24.3-145.0)
Female	56	64.9	86.3	(65.2-112.1)	Female	7	8.1	86.0	(34.5-177.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.3	nc	(nc-nc)	Male	10	7.2	139.4	(66.8-256.5)
<u>Colon / Rectum</u>					Female	5	3.4	148.9	(48.0-347.6)
Male	19	17.4	109.4	(65.8-170.8)	<u>Ovary</u>				
Female	31	19.2	161.4	(109.7-229.1)	Female	6	5.9	101.0	(36.9-219.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.1	148.0	(54.0-322.1)	Male	2	5.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	10	6.1	163.9	(78.5-301.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.3	nc	(nc-nc)	Male	58	53.2	109.0	(82.7-140.9)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.6	nc	(nc-nc)
Male	18	8.4	213.8	(126.7-337.9)	Female	2	2.4	nc	(nc-nc)
Female	3	5.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.2	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.8	nc	(nc-nc)	Male	3	4.0	nc	(nc-nc)
<u>Leukemia</u>					Female	13	12.4	105.2	(56.0-180.0)
Male	9	6.3	142.5	(65.0-270.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	5.0	nc	(nc-nc)	Female	16	14.3	111.6	(63.7-181.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	6	5.2	115.1	(42.0-250.5)	Male	225	204.6	110.0	(96.1-125.3)
Female	3	1.8	nc	(nc-nc)	Female	222	223.1	99.5	(86.8-113.5)
<u>Lung and Bronchus</u>									
Male	29	27.2	106.6	(71.4-153.1)					
Female	30	30.4	98.7	(66.6-140.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Northfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.9	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	3	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	13	14.0	92.6	(49.3-158.4)	Female	0	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.7	nc	(nc-nc)
Male	4	4.3	nc	(nc-nc)	<u>Ovary</u>				
Female	3	3.8	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	10	14.4	69.5	(33.3-127.8)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.9	nc	(nc-nc)
Male	1	2.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.5	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.0	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.4	nc	(nc-nc)	Male	38	52.0	73.0	(51.7-100.2)
Female	1	0.4	nc	(nc-nc)	Female	40	46.8	85.4	(61.0-116.3)
<u>Lung and Bronchus</u>									
Male	4	7.1	nc	(nc-nc)					
Female	4	6.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	15.8	69.6	(34.7-124.5)	Male	13	11.2	116.3	(61.8-198.8)
Female	8	5.8	137.8	(59.3-271.5)	Female	13	9.4	137.8	(73.3-235.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.5	143.3	(46.2-334.3)	Male	4	3.2	nc	(nc-nc)
Female	5	3.0	168.4	(54.3-393.1)	Female	2	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	7	9.9	70.7	(28.3-145.6)
Female	63	72.0	87.5	(67.2-112.0)	Female	12	8.3	144.8	(74.7-252.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	9	8.5	106.3	(48.5-201.7)
<u>Colon / Rectum</u>					Female	4	3.5	nc	(nc-nc)
Male	26	18.7	138.9	(90.7-203.5)	<u>Ovary</u>				
Female	29	18.1	160.2	(107.3-230.1)	Female	7	6.5	107.8	(43.2-222.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	4.6	130.7	(47.7-284.4)	Male	9	5.6	159.9	(73.0-303.6)
Female	2	1.1	nc	(nc-nc)	Female	8	5.6	142.2	(61.2-280.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.6	nc	(nc-nc)	Male	65	63.4	102.5	(79.1-130.7)
Female	0	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	3.9	nc	(nc-nc)
Male	11	9.8	112.4	(56.0-201.1)	Female	2	2.3	nc	(nc-nc)
Female	7	5.5	127.9	(51.2-263.5)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.8	180.6	(58.2-421.5)
Male	3	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	8	4.9	164.1	(70.7-323.4)
<u>Leukemia</u>					Female	15	14.8	101.5	(56.8-167.5)
Male	7	6.8	103.3	(41.4-212.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.0	119.9	(43.8-260.9)	Female	23	16.3	141.1	(89.4-211.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	6.0	198.8	(102.6-347.3)	Male	252	229.5	109.8	(96.7-124.2)
Female	0	1.8	nc	(nc-nc)	Female	252	235.2	107.1	(94.3-121.2)
<u>Lung and Bronchus</u>									
Male	28	29.5	95.0	(63.1-137.2)					
Female	30	31.1	96.6	(65.2-137.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	12.3	81.3	(38.9-149.5)	Male	5	7.9	63.1	(20.3-147.3)
Female	1	4.6	nc	(nc-nc)	Female	14	6.2	226.0	(123.4-379.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.3	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	4	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	4	7.0	nc	(nc-nc)
Female	43	49.3	87.2	(63.1-117.4)	Female	7	6.1	115.0	(46.1-237.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.6	nc	(nc-nc)	Male	3	5.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	7	2.5	276.6	(110.8-570.0)
Male	11	13.6	80.7	(40.2-144.4)	<u>Ovary</u>				
Female	9	14.1	63.8	(29.1-121.1)	Female	8	4.5	179.0	(77.1-352.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.4	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	7	4.5	154.4	(61.9-318.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	45	45.9	98.1	(71.6-131.3)
Female	3	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.9	nc	(nc-nc)
Male	4	6.7	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
Female	4	3.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	6	8.4	71.4	(26.1-155.3)
Male	6	4.8	123.9	(45.2-269.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	3.7	nc	(nc-nc)	Female	15	11.2	134.1	(75.0-221.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.3	nc	(nc-nc)	Male	132	165.6	79.7	(66.7-94.5)
Female	1	1.4	nc	(nc-nc)	Female	168	167.0	100.6	(85.9-117.0)
<u>Lung and Bronchus</u>									
Male	14	22.5	62.2	(34.0-104.4)					
Female	15	23.6	63.6	(35.6-104.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Norwood

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	34.6	60.6	(37.5-92.7)	Male	31	21.5	144.1	(97.9-204.5)
Female	11	13.9	79.0	(39.4-141.3)	Female	23	18.0	128.0	(81.1-192.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	6.0	166.5	(79.7-306.2)	Male	10	6.3	157.7	(75.5-290.1)
Female	8	5.5	145.1	(62.5-286.0)	Female	7	5.8	121.5	(48.7-250.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	24	19.1	125.9	(80.7-187.4)
Female	147	134.1	109.6	(92.6-128.9)	Female	16	17.7	90.3	(51.6-146.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	4.5	110.7	(35.7-258.3)	Male	15	14.3	104.6	(58.5-172.5)
<u>Colon / Rectum</u>					Female	4	7.2	nc	(nc-nc)
Male	51	37.0	137.9	(102.7-181.4)	<u>Ovary</u>				
Female	53	42.2	125.5	(94.0-164.2)	Female	15	12.5	120.3	(67.3-198.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	8.7	114.7	(54.9-211.0)	Male	16	11.4	139.9	(79.9-227.2)
Female	4	2.6	nc	(nc-nc)	Female	18	13.7	131.3	(77.8-207.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	2.5	198.3	(63.9-462.8)	Male	88	112.4	78.3	(62.8-96.5)
Female	2	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	7.9	139.9	(69.7-250.3)
Male	18	17.2	104.5	(61.9-165.1)	Female	7	5.4	130.1	(52.1-268.0)
Female	16	11.1	144.1	(82.3-234.0)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.3	162.4	(65.0-334.6)
Male	7	4.8	146.7	(58.8-302.3)	<u>Thyroid</u>				
Female	4	1.7	nc	(nc-nc)	Male	13	7.7	168.1	(89.4-287.4)
<u>Leukemia</u>					Female	28	23.6	118.6	(78.8-171.4)
Male	18	13.4	134.8	(79.8-213.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	10.8	74.4	(32.0-146.6)	Female	33	29.9	110.3	(75.9-154.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	10.8	129.6	(70.8-217.5)	Male	483	437.0	110.5	(100.9-120.8)
Female	2	4.0	nc	(nc-nc)	Female	526	475.7	110.6	(101.3-120.4)
<u>Lung and Bronchus</u>									
Male	64	61.0	104.9	(80.8-134.0)					
Female	83	69.1	120.2	(95.7-149.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oak Bluffs

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	5.6	89.9	(29.0-209.7)	Male	10	3.6	277.2	(132.7-509.7)
Female	0	2.2	nc	(nc-nc)	Female	0	2.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
Female	22	22.1	99.5	(62.3-150.7)	Female	1	2.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	6	6.1	97.8	(35.7-212.9)	<u>Ovary</u>				
Female	5	6.8	74.0	(23.9-172.8)	Female	2	2.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.5	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	19	20.2	94.3	(56.7-147.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	1	3.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	4	3.8	nc	(nc-nc)
Male	0	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.7	nc	(nc-nc)	Female	7	5.1	137.9	(55.2-284.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	1.9	264.4	(85.2-617.0)	Male	69	74.3	92.9	(72.3-117.6)
Female	0	0.6	nc	(nc-nc)	Female	69	77.2	89.3	(69.5-113.1)
<u>Lung and Bronchus</u>									
Male	5	10.1	49.4	(15.9-115.3)					
Female	12	11.1	108.4	(55.9-189.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oakham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.0	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	6	7.7	77.5	(28.3-168.6)	Female	2	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	0	2.3	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	8.1	147.6	(76.2-257.8)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.5	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.6	nc	(nc-nc)
Male	2	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.5	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	26	28.7	90.5	(59.1-132.6)
Female	0	0.2	nc	(nc-nc)	Female	20	24.3	82.3	(50.3-127.2)
<u>Lung and Bronchus</u>									
Male	2	3.7	nc	(nc-nc)					
Female	1	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orange

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	8.6	115.7	(55.4-212.8)	Male	4	5.7	nc	(nc-nc)
Female	2	3.2	nc	(nc-nc)	Female	3	4.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.6	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	5.0	140.3	(56.2-289.0)
Female	38	34.8	109.4	(77.4-150.1)	Female	3	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.2	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.8	nc	(nc-nc)
Male	7	9.6	73.1	(29.3-150.7)	<u>Ovary</u>				
Female	5	9.6	52.1	(16.8-121.6)	Female	1	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.4	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	34	32.5	104.8	(72.5-146.4)
Female	1	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.0	nc	(nc-nc)
Male	5	4.8	104.0	(33.5-242.6)	Female	0	1.2	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.4	109.4	(43.8-225.5)
Male	2	3.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	2.5	nc	(nc-nc)	Female	13	8.0	163.3	(86.9-279.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.0	nc	(nc-nc)	Male	120	117.7	102.0	(84.5-121.9)
Female	0	1.0	nc	(nc-nc)	Female	108	117.7	91.8	(75.3-110.8)
<u>Lung and Bronchus</u>									
Male	19	15.9	119.5	(71.9-186.6)					
Female	12	16.7	71.8	(37.0-125.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Orleans

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	16.3	97.9	(55.9-159.0)	Male	22	8.8	249.5	(156.3-377.8)
Female	5	5.5	91.4	(29.5-213.3)	Female	10	5.6	177.0	(84.7-325.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.0	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	10	7.7	129.1	(61.8-237.4)
Female	64	45.1	142.1	(109.4-181.4)	Female	5	6.5	76.9	(24.8-179.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.6	nc	(nc-nc)
Male	15	15.8	95.2	(53.2-157.0)	<u>Ovary</u>				
Female	16	15.5	102.9	(58.8-167.2)	Female	3	4.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.8	nc	(nc-nc)	Male	2	5.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	6	5.4	111.5	(40.7-242.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	42	48.4	86.8	(62.5-117.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.5	nc	(nc-nc)
Male	1	6.7	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Female	2	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.5	nc	(nc-nc)
Male	7	5.4	128.8	(51.6-265.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.7	nc	(nc-nc)	Female	15	10.7	140.0	(78.3-231.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.3	nc	(nc-nc)	Male	162	185.5	87.3	(74.4-101.8)
Female	1	1.5	nc	(nc-nc)	Female	175	167.4	104.6	(89.6-121.2)
<u>Lung and Bronchus</u>									
Male	14	28.4	49.3	(26.9-82.7)					
Female	19	27.5	69.1	(41.6-107.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Otis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	2	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	10	8.3	121.2	(58.0-222.9)	Female	3	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	1	2.7	nc	(nc-nc)	<u>Ovary</u>				
Female	1	2.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	13	9.4	138.8	(73.8-237.4)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	0	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	29	33.2	87.4	(58.5-125.5)
Female	0	0.2	nc	(nc-nc)	Female	29	27.0	107.2	(71.8-154.0)
<u>Lung and Bronchus</u>									
Male	5	4.6	108.7	(35.0-253.7)					
Female	6	3.9	155.2	(56.7-337.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Oxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	13.1	122.5	(70.0-199.0)	Male	9	9.0	100.3	(45.8-190.3)
Female	8	4.7	171.8	(74.0-338.5)	Female	7	7.4	95.2	(38.1-196.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.7	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	10	7.9	126.0	(60.3-231.8)
Female	52	56.7	91.8	(68.5-120.4)	Female	6	6.6	91.5	(33.4-199.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.1	nc	(nc-nc)	Male	8	6.7	119.4	(51.4-235.2)
<u>Colon / Rectum</u>					Female	4	2.8	nc	(nc-nc)
Male	6	15.2	39.6	(14.5-86.2)	<u>Ovary</u>				
Female	16	14.5	110.3	(63.0-179.1)	Female	5	5.1	98.3	(31.7-229.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.7	nc	(nc-nc)	Male	2	4.6	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	5	4.5	111.1	(35.8-259.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	47	50.9	92.4	(67.9-122.9)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.2	nc	(nc-nc)
Male	4	7.8	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
Female	6	4.4	137.6	(50.2-299.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.0	nc	(nc-nc)
Male	5	2.1	240.5	(77.5-561.1)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	10	11.3	88.6	(42.4-163.0)
Male	10	5.4	184.5	(88.3-339.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.9	127.8	(41.2-298.2)	Female	20	12.9	155.3	(94.8-239.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	4.9	143.4	(57.5-295.6)	Male	192	184.6	104.0	(89.8-119.8)
Female	0	1.5	nc	(nc-nc)	Female	201	185.8	108.2	(93.8-124.2)
<u>Lung and Bronchus</u>									
Male	39	24.1	161.8	(115.0-221.1)					
Female	31	25.0	123.8	(84.1-175.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Palmer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	13.3	165.9	(103.9-251.2)	Male	12	8.7	137.2	(70.8-239.7)
Female	9	5.1	175.6	(80.2-333.5)	Female	8	7.0	113.8	(49.0-224.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.5	nc	(nc-nc)	Male	0	2.6	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	7.8	nc	(nc-nc)
Female	60	53.4	112.4	(85.8-144.7)	Female	10	6.7	148.9	(71.3-273.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.8	nc	(nc-nc)	Male	6	6.3	94.7	(34.6-206.2)
<u>Colon / Rectum</u>					Female	0	2.8	nc	(nc-nc)
Male	9	15.0	60.1	(27.4-114.0)	<u>Ovary</u>				
Female	13	15.8	82.1	(43.6-140.3)	Female	4	4.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.6	nc	(nc-nc)	Male	6	4.5	132.1	(48.2-287.5)
Female	1	1.0	nc	(nc-nc)	Female	8	5.0	158.7	(68.3-312.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.1	nc	(nc-nc)	Male	36	48.1	74.9	(52.4-103.6)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	3.1	191.3	(69.9-416.4)
Male	8	7.3	108.9	(46.9-214.5)	Female	2	2.0	nc	(nc-nc)
Female	3	4.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.8	nc	(nc-nc)
Male	5	2.0	250.5	(80.7-584.5)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	7	9.7	71.8	(28.8-148.0)
Male	4	5.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.0	123.7	(39.9-288.6)	Female	11	12.0	92.0	(45.9-164.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	4.7	107.4	(34.6-250.7)	Male	171	179.3	95.4	(81.6-110.8)
Female	3	1.5	nc	(nc-nc)	Female	180	183.6	98.0	(84.2-113.4)
<u>Lung and Bronchus</u>									
Male	29	23.9	121.1	(81.1-173.9)					
Female	19	25.6	74.3	(44.7-116.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Paxton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	5.4	nc	(nc-nc)	Male	5	3.4	145.2	(46.8-339.0)
Female	2	1.7	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	2	1.0	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
Female	22	19.1	115.4	(72.3-174.7)	Female	0	2.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.0	nc	(nc-nc)
Male	0	5.9	nc	(nc-nc)	<u>Ovary</u>				
Female	6	5.1	117.2	(42.8-255.1)	Female	2	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.4	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	24	19.1	125.4	(80.3-186.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	2	2.9	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	3	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	4	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.6	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.4	nc	(nc-nc)	Female	5	4.4	114.6	(36.9-267.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	1.8	nc	(nc-nc)	Male	71	71.4	99.5	(77.7-125.5)
Female	1	0.5	nc	(nc-nc)	Female	58	63.7	91.1	(69.1-117.7)
<u>Lung and Bronchus</u>									
Male	7	9.7	71.9	(28.8-148.1)					
Female	6	8.8	67.8	(24.8-147.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peabody

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	82	72.9	112.5	(89.5-139.7)	Male	38	43.6	87.2	(61.7-119.7)
Female	36	29.2	123.4	(86.4-170.8)	Female	36	35.2	102.3	(71.6-141.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	11.5	103.9	(53.6-181.6)	Male	18	13.0	138.2	(81.9-218.4)
Female	12	10.8	111.3	(57.4-194.4)	Female	20	12.0	167.2	(102.1-258.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	5	2.2	228.3	(73.6-532.8)	Male	46	38.7	118.8	(87.0-158.4)
Female	267	266.6	100.1	(88.5-112.9)	Female	53	36.2	146.4	(109.6-191.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	12	8.4	142.9	(73.8-249.7)	Male	37	28.5	129.7	(91.3-178.8)
<u>Colon / Rectum</u>					Female	14	14.6	96.2	(52.5-161.4)
Male	72	76.4	94.2	(73.7-118.7)	<u>Ovary</u>				
Female	91	87.8	103.6	(83.4-127.2)	Female	21	24.9	84.2	(52.1-128.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	17.8	84.3	(47.2-139.1)	Male	18	23.7	75.8	(44.9-119.8)
Female	4	5.5	nc	(nc-nc)	Female	34	28.8	118.0	(81.7-164.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	4.5	nc	(nc-nc)	Male	272	226.1	120.3	(106.4-135.5)
Female	6	4.0	150.9	(55.1-328.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	16.3	79.7	(42.4-136.3)
Male	39	34.3	113.7	(80.8-155.4)	Female	9	11.2	80.1	(36.6-152.1)
Female	19	22.4	84.7	(51.0-132.3)	<u>Testis</u>				
<u>Larynx</u>					Male	13	7.1	184.1	(97.9-314.9)
Male	17	9.7	175.8	(102.3-281.4)	<u>Thyroid</u>				
Female	2	3.4	nc	(nc-nc)	Male	17	14.6	116.8	(68.0-187.1)
<u>Leukemia</u>					Female	38	43.2	88.0	(62.3-120.8)
Male	30	27.1	110.7	(74.7-158.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	30	21.7	138.0	(93.1-197.0)	Female	56	59.8	93.7	(70.8-121.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	25	21.7	115.3	(74.6-170.2)	Male	996	888.9	112.0	(105.2-119.2)
Female	9	8.2	110.1	(50.2-209.0)	Female	1024	960.0	106.7	(100.2-113.4)
<u>Lung and Bronchus</u>									
Male	130	126.5	102.7	(85.8-122.0)					
Female	172	142.8	120.4	(103.1-139.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pelham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.0	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	6	6.9	87.5	(32.0-190.5)	Female	0	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	2.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.8	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	7.2	97.4	(39.0-200.6)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	16	25.7	62.2	(35.6-101.1)
Female	0	0.2	nc	(nc-nc)	Female	12	22.6	53.2	(27.4-92.9)
<u>Lung and Bronchus</u>									
Male	0	3.6	nc	(nc-nc)					
Female	0	3.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pembroke

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	16.2	148.1	(94.8-220.3)	Male	15	11.4	131.8	(73.7-217.4)
Female	6	5.6	107.3	(39.2-233.5)	Female	11	9.2	119.4	(59.5-213.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.5	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	2	2.9	nc	(nc-nc)	Female	0	2.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	10.0	150.2	(84.0-247.7)
Female	91	72.6	125.3	(100.9-153.8)	Female	6	8.1	74.0	(27.0-161.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.7	nc	(nc-nc)	Male	8	8.6	93.0	(40.1-183.3)
<u>Colon / Rectum</u>					Female	1	3.5	nc	(nc-nc)
Male	27	19.0	142.0	(93.6-206.6)	<u>Ovary</u>				
Female	19	17.4	109.0	(65.6-170.2)	Female	4	6.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.7	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	5	5.4	93.0	(30.0-217.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	74	65.5	113.1	(88.8-141.9)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.0	nc	(nc-nc)
Male	12	10.0	120.0	(61.9-209.6)	Female	1	2.1	nc	(nc-nc)
Female	6	5.5	109.7	(40.1-238.8)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	4.8	nc	(nc-nc)
<u>Leukemia</u>					Female	22	14.5	151.2	(94.7-229.0)
Male	9	6.8	131.9	(60.2-250.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.8	125.1	(45.7-272.3)	Female	17	16.6	102.5	(59.7-164.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	6.2	80.5	(26.0-188.0)	Male	262	234.3	111.8	(98.7-126.2)
Female	0	1.8	nc	(nc-nc)	Female	268	232.7	115.2	(101.8-129.8)
<u>Lung and Bronchus</u>									
Male	36	30.5	117.9	(82.6-163.2)					
Female	44	30.9	142.5	(103.5-191.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pepperell

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	10.1	69.2	(27.7-142.5)	Male	8	7.3	109.8	(47.3-216.4)
Female	2	3.5	nc	(nc-nc)	Female	2	5.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.3	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	6.4	124.5	(53.6-245.4)
Female	47	46.3	101.6	(74.7-135.1)	Female	5	5.1	98.8	(31.8-230.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.7	nc	(nc-nc)	Male	3	5.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	2.2	nc	(nc-nc)
Male	10	12.2	81.7	(39.1-150.3)	<u>Ovary</u>				
Female	16	11.0	145.9	(83.3-236.9)	Female	2	4.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.0	164.6	(53.0-384.1)	Male	3	3.7	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	5	3.3	150.3	(48.4-350.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	36	42.4	84.9	(59.5-117.6)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	2.5	nc	(nc-nc)
Male	6	6.5	92.6	(33.8-201.5)	Female	0	1.3	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	6	3.2	187.7	(68.5-408.6)
<u>Leukemia</u>					Female	4	9.3	nc	(nc-nc)
Male	7	4.4	160.6	(64.3-330.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.0	167.1	(53.8-389.9)	Female	11	10.6	104.1	(51.9-186.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.1	nc	(nc-nc)	Male	147	150.5	97.7	(82.5-114.8)
Female	0	1.1	nc	(nc-nc)	Female	138	146.7	94.1	(79.0-111.2)
<u>Lung and Bronchus</u>									
Male	19	19.1	99.5	(59.9-155.4)					
Female	16	19.0	84.2	(48.1-136.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Peru

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.9	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	3.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.4	nc	(nc-nc)	Male	10	13.2	75.6	(36.2-139.1)
Female	0	0.1	nc	(nc-nc)	Female	4	10.2	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	1	1.7	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Petersham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	1.8	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	4	6.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.7	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.4	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	13	23.8	54.7	(29.1-93.5)
Female	0	0.2	nc	(nc-nc)	Female	15	20.7	72.6	(40.6-119.8)
<u>Lung and Bronchus</u>									
Male	3	3.3	nc	(nc-nc)					
Female	0	3.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Phillipston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.6	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	5	6.5	76.5	(24.6-178.4)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.5	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	7	6.7	104.1	(41.7-214.5)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	4	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	17	23.8	71.4	(41.6-114.4)
Female	0	0.2	nc	(nc-nc)	Female	18	20.2	88.9	(52.7-140.6)
<u>Lung and Bronchus</u>									
Male	2	3.0	nc	(nc-nc)					
Female	3	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Pittsfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	57	57.2	99.6	(75.4-129.0)	Male	29	35.3	82.1	(54.9-117.9)
Female	26	21.6	120.1	(78.5-176.0)	Female	31	27.9	111.1	(75.4-157.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	9.7	154.0	(86.1-254.1)	Male	9	10.5	85.7	(39.1-162.7)
Female	7	8.7	80.9	(32.4-166.7)	Female	5	9.0	55.5	(17.9-129.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.8	nc	(nc-nc)	Male	34	31.3	108.7	(75.2-151.8)
Female	210	211.9	99.1	(86.2-113.5)	Female	33	27.7	119.3	(82.1-167.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	6.9	129.7	(59.2-246.3)	Male	28	23.9	117.1	(77.8-169.2)
<u>Colon / Rectum</u>					Female	6	11.3	53.2	(19.4-115.8)
Male	64	61.0	104.9	(80.7-133.9)	<u>Ovary</u>				
Female	86	65.2	131.9	(105.5-162.9)	Female	15	19.7	76.3	(42.7-125.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	26	14.5	178.8	(116.8-262.0)	Male	19	19.0	100.2	(60.3-156.5)
Female	4	4.1	nc	(nc-nc)	Female	15	21.2	70.6	(39.5-116.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.9	nc	(nc-nc)	Male	179	188.8	94.8	(81.4-109.8)
Female	2	3.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	13.0	53.8	(21.5-110.8)
Male	30	28.5	105.2	(71.0-150.2)	Female	4	8.3	nc	(nc-nc)
Female	21	17.5	120.1	(74.3-183.7)	<u>Testis</u>				
<u>Larynx</u>					Male	9	6.3	143.5	(65.5-272.4)
Male	7	8.0	87.8	(35.2-180.9)	<u>Thyroid</u>				
Female	3	2.7	nc	(nc-nc)	Male	14	12.5	112.2	(61.3-188.3)
<u>Leukemia</u>					Female	24	36.4	65.9	(42.2-98.1)
Male	19	21.9	86.9	(52.3-135.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	16.7	54.0	(24.7-102.6)	Female	43	48.0	89.5	(64.8-120.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	21	18.1	116.3	(72.0-177.8)	Male	741	724.1	102.3	(95.1-110.0)
Female	7	6.3	111.9	(44.8-230.6)	Female	759	745.4	101.8	(94.7-109.3)
<u>Lung and Bronchus</u>									
Male	112	101.4	110.5	(90.9-132.9)					
Female	144	108.7	132.4	(111.7-155.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	3.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.2	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.6	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.3	nc	(nc-nc)	Male	14	13.1	107.0	(58.5-179.6)
Female	0	0.1	nc	(nc-nc)	Female	8	10.4	76.7	(33.0-151.1)
<u>Lung and Bronchus</u>									
Male	5	1.8	277.4	(89.4-647.3)					
Female	1	1.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plainville

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	8.1	148.8	(76.8-260.0)	Male	5	5.5	91.4	(29.4-213.2)
Female	2	3.1	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.3	nc	(nc-nc)	Male	9	4.8	186.5	(85.1-354.1)
Female	32	35.5	90.2	(61.7-127.4)	Female	3	4.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.3	nc	(nc-nc)	Male	4	4.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	1.8	nc	(nc-nc)
Male	8	9.1	87.5	(37.7-172.4)	<u>Ovary</u>				
Female	10	9.4	106.1	(50.8-195.1)	Female	4	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.2	nc	(nc-nc)	Male	6	2.8	214.7	(78.4-467.3)
Female	1	0.6	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.7	nc	(nc-nc)	Male	33	30.5	108.1	(74.4-151.9)
Female	0	0.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	10	4.7	213.4	(102.2-392.5)	Female	1	1.2	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	2	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	3	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	7	6.8	102.7	(41.2-211.7)
Male	3	3.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	2.5	198.8	(64.1-463.9)	Female	7	8.0	87.4	(35.0-180.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	131	112.0	116.9	(97.8-138.8)
Female	0	1.0	nc	(nc-nc)	Female	117	118.4	98.8	(81.7-118.5)
<u>Lung and Bronchus</u>									
Male	14	14.9	93.9	(51.3-157.5)					
Female	18	16.6	108.4	(64.2-171.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plymouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	72	60.0	120.0	(93.9-151.1)	Male	62	40.1	154.7	(118.6-198.4)
Female	21	22.2	94.5	(58.5-144.5)	Female	63	32.3	195.2	(150.0-249.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.8	85.0	(40.7-156.4)	Male	13	11.7	111.3	(59.2-190.4)
Female	11	10.0	109.9	(54.8-196.7)	Female	8	9.6	83.5	(35.9-164.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.9	nc	(nc-nc)	Male	43	35.2	122.1	(88.3-164.4)
Female	296	249.6	118.6	(105.5-132.9)	Female	35	30.2	115.8	(80.7-161.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	8.8	nc	(nc-nc)	Male	38	29.2	130.3	(92.2-178.9)
<u>Colon / Rectum</u>					Female	13	12.7	102.2	(54.4-174.8)
Male	84	67.2	124.9	(99.7-154.7)	<u>Ovary</u>				
Female	82	67.4	121.6	(96.7-150.9)	Female	26	22.8	114.1	(74.5-167.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	23	16.8	137.3	(87.0-206.0)	Male	23	20.9	110.3	(69.9-165.5)
Female	1	4.3	nc	(nc-nc)	Female	20	21.7	92.0	(56.2-142.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	5.0	nc	(nc-nc)	Male	264	229.7	115.0	(101.5-129.7)
Female	3	3.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	17	14.3	119.2	(69.4-190.8)
Male	31	34.3	90.4	(61.4-128.3)	Female	9	8.5	106.5	(48.6-202.1)
Female	20	19.7	101.8	(62.1-157.2)	<u>Testis</u>				
<u>Larynx</u>					Male	3	8.5	nc	(nc-nc)
Male	13	9.3	140.1	(74.5-239.5)	<u>Thyroid</u>				
Female	1	3.1	nc	(nc-nc)	Male	17	16.0	106.0	(61.7-169.8)
<u>Leukemia</u>					Female	70	46.2	151.5	(118.1-191.4)
Male	33	24.2	136.3	(93.8-191.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	17.8	89.7	(51.2-145.6)	Female	58	58.4	99.4	(75.5-128.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	21	21.3	98.8	(61.1-151.1)	Male	956	829.1	115.3	(108.1-122.9)
Female	5	6.9	72.9	(23.5-170.2)	Female	961	837.5	114.7	(107.6-122.2)
<u>Lung and Bronchus</u>									
Male	113	110.6	102.2	(84.2-122.9)					
Female	123	116.1	105.9	(88.0-126.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Plympton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.2	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	9	12.6	71.2	(32.5-135.3)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.4	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.6	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	<u>Ovary</u>				
Female	4	3.0	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	15	13.4	112.1	(62.7-184.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.2	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.4	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.8	nc	(nc-nc)	Female	1	3.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.2	nc	(nc-nc)	Male	38	45.8	83.0	(58.7-113.9)
Female	0	0.3	nc	(nc-nc)	Female	39	40.3	96.8	(68.8-132.3)
<u>Lung and Bronchus</u>									
Male	3	6.1	nc	(nc-nc)					
Female	7	5.4	128.6	(51.5-265.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Princeton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.8	158.7	(58.0-345.5)	Male	2	2.7	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	14	15.6	89.7	(49.0-150.5)	Female	3	1.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	5	2.1	233.7	(75.3-545.3)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	5	4.5	111.8	(36.0-261.0)	<u>Ovary</u>				
Female	1	3.7	nc	(nc-nc)	Female	6	1.4	430.1	(157.0-936.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.2	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	24	16.7	143.8	(92.1-213.9)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	3	2.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	5	1.2	431.7	(139.1-1007.5)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	3	2.9	nc	(nc-nc)
Male	2	1.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.0	nc	(nc-nc)	Female	3	3.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)	Male	63	56.4	111.8	(85.9-143.0)
Female	0	0.4	nc	(nc-nc)	Female	49	49.3	99.3	(73.5-131.3)
<u>Lung and Bronchus</u>									
Male	2	7.3	nc	(nc-nc)					
Female	3	6.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Provincetown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	5.2	nc	(nc-nc)	Male	7	3.4	205.6	(82.4-423.7)
Female	2	1.6	nc	(nc-nc)	Female	3	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
Female	23	16.8	137.2	(87.0-205.9)	Female	1	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	5	2.6	194.1	(62.5-452.9)
<u>Colon / Rectum</u>					Female	1	0.9	nc	(nc-nc)
Male	6	5.9	101.3	(37.0-220.4)	<u>Ovary</u>				
Female	5	4.7	106.1	(34.2-247.6)	Female	2	1.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.5	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	0.3	nc	(nc-nc)	Male	14	20.1	69.8	(38.1-117.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.2	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	2.6	nc	(nc-nc)
Male	0	1.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.1	nc	(nc-nc)	Female	4	4.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	1.9	nc	(nc-nc)	Male	77	71.0	108.4	(85.5-135.5)
Female	1	0.5	nc	(nc-nc)	Female	68	56.8	119.7	(93.0-151.8)
<u>Lung and Bronchus</u>									
Male	11	9.5	115.8	(57.7-207.3)					
Female	10	8.4	119.4	(57.1-219.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Quincy

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	81	98.3	82.4	(65.4-102.4)	Male	49	64.0	76.6	(56.7-101.3)
Female	31	39.7	78.2	(53.1-111.0)	Female	64	55.6	115.1	(88.6-147.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	18.4	87.0	(49.7-141.3)	Male	16	18.5	86.6	(49.4-140.6)
Female	11	16.7	66.0	(32.9-118.0)	Female	10	16.6	60.1	(28.8-110.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	3.1	nc	(nc-nc)	Male	49	56.4	86.8	(64.2-114.8)
Female	380	403.4	94.2	(85.0-104.2)	Female	58	51.9	111.7	(84.8-144.3)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	19	14.5	130.7	(78.6-204.1)	Male	61	44.0	138.8	(106.1-178.3)
<u>Colon / Rectum</u>					Female	22	21.2	103.5	(64.9-156.8)
Male	137	107.8	127.0	(106.7-150.2)	<u>Ovary</u>				
Female	117	121.0	96.7	(80.0-115.9)	Female	37	37.5	98.5	(69.4-135.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	30	25.7	116.5	(78.6-166.4)	Male	30	33.2	90.5	(61.0-129.2)
Female	9	7.5	119.5	(54.5-226.8)	Female	37	39.0	95.0	(66.9-130.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	8.5	82.8	(33.2-170.6)	Male	297	339.5	87.5	(77.8-98.0)
Female	7	7.3	95.4	(38.2-196.6)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	25	22.9	109.4	(70.8-161.5)
Male	51	52.4	97.4	(72.5-128.1)	Female	11	15.4	71.7	(35.7-128.2)
Female	39	32.8	118.8	(84.4-162.4)	<u>Testis</u>				
<u>Larynx</u>					Male	13	15.5	83.8	(44.6-143.3)
Male	14	14.2	98.6	(53.8-165.4)	<u>Thyroid</u>				
Female	7	5.0	140.9	(56.4-290.3)	Male	20	24.9	80.2	(49.0-123.9)
<u>Leukemia</u>					Female	75	77.9	96.3	(75.7-120.7)
Male	26	39.0	66.7	(43.5-97.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	28	31.3	89.4	(59.4-129.3)	Female	87	91.0	95.6	(76.5-117.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	58	32.4	178.8	(135.8-231.2)	Male	1290	1295.2	99.6	(94.2-105.2)
Female	13	11.6	112.3	(59.7-192.0)	Female	1413	1412.7	100.0	(94.9-105.4)
<u>Lung and Bronchus</u>									
Male	214	175.9	121.7	(105.9-139.1)					
Female	239	199.3	119.9	(105.2-136.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Randolph

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	32.3	111.4	(78.0-154.2)	Male	13	21.4	60.7	(32.3-103.8)
Female	6	12.6	47.8	(17.5-104.0)	Female	18	18.4	97.7	(57.9-154.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	6.3	94.7	(34.6-206.1)	Male	5	6.2	80.3	(25.9-187.4)
Female	7	5.6	124.1	(49.7-255.7)	Female	9	5.4	167.5	(76.4-318.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	17	18.9	90.0	(52.4-144.1)
Female	120	139.0	86.3	(71.6-103.2)	Female	17	17.0	100.2	(58.3-160.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	5.0	180.8	(82.5-343.3)	Male	5	15.4	32.4	(10.5-75.7)
<u>Colon / Rectum</u>					Female	8	7.1	112.6	(48.5-221.9)
Male	40	36.2	110.5	(78.9-150.4)	<u>Ovary</u>				
Female	42	38.5	109.1	(78.6-147.4)	Female	10	12.7	78.6	(37.6-144.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	8.8	68.0	(24.8-148.1)	Male	13	11.1	116.7	(62.1-199.5)
Female	3	2.4	nc	(nc-nc)	Female	11	12.2	90.1	(44.9-161.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.8	nc	(nc-nc)	Male	123	119.1	103.3	(85.8-123.2)
Female	0	2.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	7.6	91.7	(36.7-188.9)
Male	22	18.0	122.1	(76.5-184.8)	Female	6	4.8	124.3	(45.4-270.5)
Female	10	11.0	90.9	(43.5-167.1)	<u>Testis</u>				
<u>Larynx</u>					Male	0	4.7	nc	(nc-nc)
Male	7	4.9	143.0	(57.3-294.7)	<u>Thyroid</u>				
Female	0	1.7	nc	(nc-nc)	Male	4	8.5	nc	(nc-nc)
<u>Leukemia</u>					Female	24	26.8	89.6	(57.4-133.3)
Male	13	13.1	99.1	(52.7-169.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	10.2	49.2	(15.9-114.9)	Female	31	31.7	97.8	(66.5-138.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	15	11.3	132.2	(73.9-218.0)	Male	414	440.0	94.1	(85.2-103.6)
Female	7	3.8	183.3	(73.4-377.7)	Female	431	470.6	91.6	(83.1-100.7)
<u>Lung and Bronchus</u>									
Male	54	58.9	91.7	(68.9-119.7)					
Female	53	65.1	81.4	(60.9-106.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Raynham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	14.4	117.8	(68.6-188.6)	Male	7	9.5	74.1	(29.7-152.6)
Female	6	5.2	116.2	(42.4-252.9)	Female	11	7.5	146.2	(72.9-261.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	3	2.3	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	8	8.4	95.8	(41.2-188.7)
Female	59	58.3	101.2	(77.0-130.5)	Female	8	7.0	113.7	(49.0-224.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	2.1	242.9	(78.3-566.9)	Male	4	6.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	3.0	nc	(nc-nc)
Male	16	16.0	99.7	(57.0-161.9)	<u>Ovary</u>				
Female	19	15.8	120.4	(72.5-188.0)	Female	4	5.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.9	127.3	(41.0-297.2)	Male	6	4.9	121.5	(44.4-264.4)
Female	4	1.0	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	1.1	nc	(nc-nc)	Male	53	52.8	100.4	(75.2-131.3)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.4	nc	(nc-nc)
Male	11	8.0	137.6	(68.6-246.2)	Female	4	2.0	nc	(nc-nc)
Female	9	4.6	196.6	(89.7-373.2)	<u>Testis</u>				
<u>Larynx</u>					Male	9	1.8	489.3	(223.3-928.9)
Male	1	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	6	3.7	163.7	(59.8-356.2)
<u>Leukemia</u>					Female	22	10.9	201.1	(126.0-304.4)
Male	5	5.8	86.5	(27.9-201.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.2	143.6	(52.5-312.7)	Female	11	13.3	82.5	(41.2-147.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.0	nc	(nc-nc)	Male	215	194.7	110.4	(96.2-126.2)
Female	2	1.6	nc	(nc-nc)	Female	235	195.2	120.4	(105.5-136.8)
<u>Lung and Bronchus</u>									
Male	33	26.3	125.5	(86.4-176.3)					
Female	33	27.1	121.8	(83.8-171.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Reading

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	31	26.4	117.2	(79.6-166.4)	Male	25	17.3	144.8	(93.7-213.7)
Female	6	10.2	59.0	(21.6-128.5)	Female	15	14.3	105.1	(58.8-173.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	5.1	118.2	(43.2-257.3)	Male	4	5.1	nc	(nc-nc)
Female	5	4.4	112.7	(36.3-263.0)	Female	4	4.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	17	15.3	111.1	(64.7-177.8)
Female	130	110.0	118.2	(98.8-140.4)	Female	9	13.5	66.6	(30.4-126.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	3.8	nc	(nc-nc)	Male	6	12.3	48.6	(17.8-105.8)
<u>Colon / Rectum</u>					Female	5	5.6	88.8	(28.6-207.1)
Male	31	29.6	104.9	(71.2-148.9)	<u>Ovary</u>				
Female	31	31.3	99.0	(67.3-140.6)	Female	9	10.0	90.0	(41.1-170.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	7.1	155.2	(77.4-277.7)	Male	10	9.0	111.0	(53.1-204.1)
Female	3	1.9	nc	(nc-nc)	Female	7	9.9	70.5	(28.3-145.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.1	nc	(nc-nc)	Male	74	94.1	78.6	(61.7-98.7)
Female	4	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	6.2	96.4	(35.2-209.9)
Male	9	14.5	62.1	(28.4-118.0)	Female	2	3.9	nc	(nc-nc)
Female	4	8.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	3.3	nc	(nc-nc)
Male	4	3.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	9	6.7	134.9	(61.6-256.2)
<u>Leukemia</u>					Female	32	20.2	158.1	(108.1-223.2)
Male	12	10.6	112.7	(58.2-197.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	8.2	134.8	(67.2-241.2)	Female	31	24.7	125.3	(85.1-177.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	9.1	98.9	(45.1-187.7)	Male	329	353.5	93.1	(83.3-103.7)
Female	6	3.0	197.2	(72.0-429.3)	Female	407	373.2	109.1	(98.7-120.2)
<u>Lung and Bronchus</u>									
Male	45	47.6	94.5	(68.9-126.4)					
Female	50	52.0	96.2	(71.4-126.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rehoboth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	12.4	80.4	(38.5-147.9)	Male	8	8.5	94.2	(40.6-185.6)
Female	3	3.9	nc	(nc-nc)	Female	3	6.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.5	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	6	7.5	80.4	(29.4-175.0)
Female	48	50.1	95.8	(70.6-127.0)	Female	7	5.6	124.1	(49.7-255.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	2	6.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	2.4	nc	(nc-nc)
Male	11	14.3	76.8	(38.3-137.4)	<u>Ovary</u>				
Female	12	12.3	97.7	(50.4-170.6)	Female	2	4.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.6	nc	(nc-nc)	Male	2	4.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	5	3.8	131.7	(42.4-307.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	47	50.4	93.2	(68.5-123.9)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	3.0	nc	(nc-nc)
Male	8	7.5	107.3	(46.2-211.4)	Female	0	1.5	nc	(nc-nc)
Female	6	3.8	158.3	(57.8-344.6)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.6	nc	(nc-nc)
Male	1	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.6	nc	(nc-nc)	Male	1	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	9	9.6	94.1	(42.9-178.6)
Male	4	5.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.3	nc	(nc-nc)	Female	16	11.6	137.8	(78.7-223.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	4.7	nc	(nc-nc)	Male	144	177.5	81.1	(68.4-95.5)
Female	2	1.3	nc	(nc-nc)	Female	151	161.1	93.7	(79.4-109.9)
<u>Lung and Bronchus</u>									
Male	28	23.3	120.0	(79.7-173.4)					
Female	18	21.6	83.2	(49.3-131.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Revere

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	Obs	Exp	SIR	95% CI		Obs	Exp	SIR	95% CI
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	47	54.8	85.7	(63.0-114.0)	Male	22	35.3	62.4	(39.1-94.4)
Female	19	20.7	91.8	(55.2-143.4)	Female	26	29.0	89.6	(58.5-131.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	10.3	126.7	(67.4-216.7)	Male	10	10.2	98.0	(46.9-180.2)
Female	8	8.9	89.7	(38.6-176.8)	Female	12	8.7	138.2	(71.3-241.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.7	nc	(nc-nc)	Male	31	31.3	99.1	(67.3-140.7)
Female	214	212.3	100.8	(87.7-115.2)	Female	28	27.2	103.0	(68.4-148.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	7.6	65.7	(21.2-153.3)	Male	24	23.8	100.8	(64.5-149.9)
<u>Colon / Rectum</u>					Female	12	11.1	108.1	(55.8-188.8)
Male	73	59.8	122.1	(95.7-153.6)	<u>Ovary</u>				
Female	43	63.3	67.9	(49.1-91.5)	Female	14	19.7	71.2	(38.9-119.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	14.1	56.8	(24.5-112.0)	Male	17	18.3	92.8	(54.0-148.6)
Female	5	3.9	126.7	(40.8-295.7)	Female	15	20.4	73.7	(41.2-121.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	7	4.7	148.3	(59.4-305.6)	Male	120	183.3	65.5	(54.3-78.3)
Female	4	3.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	23	12.6	181.9	(115.2-272.9)
Male	36	28.6	125.8	(88.1-174.1)	Female	6	8.0	74.9	(27.3-163.0)
Female	35	17.3	202.4	(140.9-281.5)	<u>Testis</u>				
<u>Larynx</u>					Male	9	8.5	105.3	(48.0-199.9)
Male	10	7.7	129.2	(61.9-237.6)	<u>Thyroid</u>				
Female	8	2.6	308.0	(132.6-606.8)	Male	13	13.6	95.8	(50.9-163.8)
<u>Leukemia</u>					Female	47	40.8	115.1	(84.6-153.1)
Male	30	21.9	137.2	(92.5-195.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	16.6	72.1	(37.2-125.9)	Female	39	47.5	82.0	(58.3-112.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	32	17.6	182.0	(124.5-256.9)	Male	707	711.8	99.3	(92.1-106.9)
Female	5	6.1	82.5	(26.6-192.6)	Female	758	741.2	102.3	(95.1-109.8)
<u>Lung and Bronchus</u>									
Male	127	97.3	130.6	(108.8-155.3)					
Female	143	104.5	136.8	(115.3-161.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Richmond

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	6	8.6	69.5	(25.4-151.4)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	2	2.8	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.7	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	13	10.2	127.1	(67.6-217.4)
Female	1	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.4	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	1	2.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	28	35.6	78.8	(52.3-113.8)
Female	0	0.2	nc	(nc-nc)	Female	21	28.7	73.2	(45.3-112.0)
<u>Lung and Bronchus</u>									
Male	2	5.1	nc	(nc-nc)					
Female	2	4.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rochester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.4	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
Female	26	22.1	117.5	(76.7-172.1)	Female	3	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	5	6.3	79.3	(25.6-185.1)	<u>Ovary</u>				
Female	6	5.2	114.4	(41.8-249.0)	Female	2	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.6	nc	(nc-nc)	Male	2	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	29	22.7	127.7	(85.5-183.4)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.3	nc	(nc-nc)
Male	3	3.3	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.7	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.3	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	3	5.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.1	nc	(nc-nc)	Male	73	78.6	92.9	(72.8-116.8)
Female	0	0.6	nc	(nc-nc)	Female	65	70.1	92.7	(71.5-118.1)
<u>Lung and Bronchus</u>									
Male	12	10.1	118.5	(61.2-207.0)					
Female	3	9.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	17.4	126.2	(79.1-191.1)	Male	9	11.5	78.0	(35.6-148.0)
Female	12	7.0	172.3	(88.9-301.0)	Female	17	10.0	169.2	(98.5-271.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	3.4	233.5	(100.5-460.1)	Male	2	3.3	nc	(nc-nc)
Female	4	3.1	nc	(nc-nc)	Female	0	3.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	12	10.2	117.6	(60.7-205.5)
Female	79	76.3	103.6	(82.0-129.1)	Female	13	9.3	139.1	(74.0-237.8)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	10	8.3	120.9	(57.9-222.3)
<u>Colon / Rectum</u>					Female	6	3.9	154.2	(56.3-335.5)
Male	25	19.6	127.8	(82.7-188.7)	<u>Ovary</u>				
Female	28	21.3	131.5	(87.4-190.1)	Female	4	7.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.7	105.9	(34.1-247.1)	Male	7	6.0	117.0	(46.9-241.1)
Female	1	1.3	nc	(nc-nc)	Female	7	6.8	103.3	(41.4-213.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.5	nc	(nc-nc)	Male	70	63.2	110.8	(86.4-140.0)
Female	0	1.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	4.1	nc	(nc-nc)
Male	12	9.7	123.8	(63.9-216.2)	Female	5	2.7	187.3	(60.4-437.1)
Female	15	6.1	247.0	(138.1-407.4)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.5	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	4.6	nc	(nc-nc)
<u>Leukemia</u>					Female	22	14.5	152.1	(95.3-230.3)
Male	13	7.1	183.0	(97.4-313.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	5.6	230.7	(122.7-394.6)	Female	22	17.2	127.6	(79.9-193.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.1	nc	(nc-nc)	Male	274	236.0	116.1	(102.7-130.7)
Female	4	2.1	nc	(nc-nc)	Female	329	258.9	127.1	(113.7-141.6)
<u>Lung and Bronchus</u>									
Male	38	31.6	120.3	(85.1-165.1)					
Female	55	36.3	151.7	(114.3-197.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rockport

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	10.9	100.6	(50.2-180.0)	Male	9	6.6	135.6	(61.9-257.4)
Female	3	4.4	nc	(nc-nc)	Female	8	5.4	148.3	(63.9-292.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.7	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.3	nc	(nc-nc)	Male	6	5.8	103.1	(37.7-224.4)
Female	42	43.2	97.3	(70.1-131.5)	Female	7	5.6	124.7	(49.9-256.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.3	nc	(nc-nc)	Male	7	4.7	149.8	(60.0-308.6)
<u>Colon / Rectum</u>					Female	5	2.3	215.6	(69.5-503.1)
Male	8	11.5	69.4	(29.9-136.8)	<u>Ovary</u>				
Female	12	13.0	92.0	(47.5-160.8)	Female	2	4.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	2.9	nc	(nc-nc)	Male	3	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	4	4.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	42	39.6	106.0	(76.4-143.3)
Female	2	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.5	nc	(nc-nc)
Male	7	5.5	126.9	(50.8-261.5)	Female	2	1.6	nc	(nc-nc)
Female	2	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	1.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
<u>Leukemia</u>					Female	9	6.5	138.3	(63.1-262.5)
Male	5	4.0	125.4	(40.4-292.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.2	nc	(nc-nc)	Female	10	10.3	97.2	(46.5-178.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.5	nc	(nc-nc)	Male	140	141.0	99.3	(83.5-117.2)
Female	1	1.3	nc	(nc-nc)	Female	141	150.6	93.6	(78.8-110.4)
<u>Lung and Bronchus</u>									
Male	17	19.8	85.8	(50.0-137.4)					
Female	8	22.6	35.4	(15.2-69.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowe

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.6	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.2	nc	(nc-nc)	Male	5	9.7	51.6	(16.6-120.4)
Female	0	0.1	nc	(nc-nc)	Female	2	7.6	nc	(nc-nc)
<u>Lung and Bronchus</u>									
Male	0	1.4	nc	(nc-nc)					
Female	0	1.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Rowley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.7	104.9	(38.3-228.3)	Male	3	4.0	nc	(nc-nc)
Female	1	2.0	nc	(nc-nc)	Female	4	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	2	1.0	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.5	nc	(nc-nc)
Female	27	24.8	108.7	(71.6-158.1)	Female	4	2.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.9	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	3	6.8	nc	(nc-nc)	<u>Ovary</u>				
Female	6	6.3	95.9	(35.0-208.7)	Female	2	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	1.7	296.3	(95.5-691.4)	Male	4	2.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	25	23.6	105.8	(68.5-156.2)
Female	1	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.4	nc	(nc-nc)
Male	2	3.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	7	4.8	145.3	(58.2-299.4)
Male	3	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.7	nc	(nc-nc)	Female	5	5.7	88.2	(28.4-205.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	2.3	nc	(nc-nc)	Male	73	83.5	87.4	(68.5-109.9)
Female	0	0.6	nc	(nc-nc)	Female	84	80.0	105.0	(83.7-129.9)
<u>Lung and Bronchus</u>									
Male	9	10.8	83.6	(38.2-158.8)					
Female	4	10.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Royalston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
Female	7	5.2	133.7	(53.6-275.4)	Female	1	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.2	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	7	6.2	113.0	(45.3-232.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.0	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	19	21.4	88.6	(53.3-138.4)
Female	0	0.1	nc	(nc-nc)	Female	18	16.5	109.0	(64.6-172.3)
<u>Lung and Bronchus</u>									
Male	3	2.8	nc	(nc-nc)					
Female	3	2.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;